Egfr-tkis - OmicsDI

Show results for

Unknown (1655)
Genomics (140)
Transcriptomics (80)
Proteomics (29)
Other (6)
Models (1)
Clinical (1)
Methylation profiling (1)

Organisms

Homo sapiens (132)
Mus musculus (7)
Betapolyomavirus hominis (1)
Betapolyomavirus macacae (1)
Herpesvirus saimiri (strain 11) (1)
Human alphaherpesvirus 1 (1)
Human alphaherpesvirus 2 (1)
Human betaherpesvirus 5 (1)
Human betaherpesvirus 6B (1)
Human gammaherpesvirus 8 (1)
Human immunodeficiency virus 1 (1)
JC polyomavirus (1)
Macacine alphaherpesvirus 1 (1)
Merkel cell polyomavirus (1)
human gammaherpesvirus 4 (1)

Organisms

Homo sapiens (90)
Mus musculus (4)
unidentified (1)
human gut metagenome (1)

Repository

ENA (117)
geo (85)
pride (20)
biostudies-arrayexpress (18)
EGA (6)
iProX (6)
jPOST (2)
BioModels (1)
GPMDB (1)
MassIVE (1)

Tissue

Cell culture (6)
Lung (5)
Lung epithelium (3)
Permanent cell line cell (2)
Epithelial cell (1)

Disease

Lung adenocarcinoma (5)
Lung cancer (3)
Non-small cell lung carcinoma (2)
Melanoma (1)
Not Available (1)

Technology Type

Mass Spectrometry (20)
Shotgun proteomics (10)
MSE (3)
Affinity purification coupled with mass spectrometry proteomics (2)
Bottom-up proteomics (2)
AB 5500 Genetic Analyzer (1)
HiSeq X Ten, Illumina HiSeq 2500, ILLUMINA (1)
Illumina HiSeq 2000 (1)
Illumina HiSeq 2500, Illumina HiSeq 2000 (ILLUMINA), Illumina HiSeq 2000, Illumina (1)
Data-dependent acquisition (1)
Data-independent acquisition (1)
Gel-based experiment (1)
Top-down proteomics (1)

Instrument Platform

Instrument (1)
Q Exactive (1)

Publication Date

2025 (20)
2024 (16)
2016 (11)
2023 (11)
2022 (11)
2026 (8)
2019 (8)
2015 (7)
2017 (7)
2018 (6)
2014 (5)
2012 (5)
2021 (5)
2020 (5)
2013 (2)
2009 (2)
2008 (2)
2010 (1)
2007 (1)

IsPrivate

False (1)

First Public Date

2025 (20)
2024 (20)
2023 (13)
2014 (11)
2026 (9)
2022 (7)
2020 (7)
2017 (7)
2021 (6)
2019 (6)
2018 (5)
2016 (3)
2015 (3)

Modelling Approach

Ordinary differential equation model (1)

Study status

Completed (1)

Study type

Transcription profiling by array (12)
Comparative genomic hybridization by array (3)
DNA-seq (1)
RNA-seq of coding RNA (1)
RNA-seq of non coding RNA (1)
Interventional (1)

Release Date

2021 (226)
2022 (205)
2023 (198)
2025 (176)
2020 (147)
2024 (141)
2019 (120)
2016 (89)
2018 (87)
2017 (81)
2015 (62)
2014 (39)
2013 (26)
2026 (21)
2012 (17)
2011 (15)
2010 (8)
2009 (7)
2007 (4)
2008 (3)
2006 (1)

Lab affiliation

Moffitt Cancer Center Tampa, FL, USA (3)
Yale Cancer Biology Institute (2)
City of Hope Beckman Research Institute (1)
Debora Bonenfant, Novartis Institutes for Biomedical research, Basel, Switzerland (1)
Department of Biochemistry, Sapporo Medical University School of Medicine (1)
Imperial College London (1)
Institute of Bioinformatics, Bangalore, Karnataka, India (1)
Institute of Biological Chemistry, Academia Sinica, Taiwan. (1)
Institute of Chemistry, Academia Sinica, Taipei, Taiwan (1)
Shenyang Pharmaceutical University (1)
THORACIC & GI ONCOLOGY BRANCH, NCI, NIH, Bethesda, MD 20892 (1)
The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China. (1)
The Second Hospital of Dalian Medical University (1)
Thoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD (1)
Thoracic and GI Oncology Branch, NCI, NIH (1)
Yale cancer biology institute (1)
Zhejiang University (1)

Location

United States (1)

Keyword

AXL inhibitor (1)
Advanced Malignancy (1)
BRAF-Mutated CRC (1)
BRAF-Mutated Melanoma with immunotherapy progression (1)
EGFR+ NSCLC with progression on ≤2 lines of oral TKIs (1)
First in human (1)
KRAS-Mutated CRC (1)
NRAS-Mutated CRC (1)
Persistent/Recurrent Ovarian Cancer (1)
Phase 1a / 1b (1)
Solid Tumors with immunotherapy progression (1)
Tolero (1)

Previous page
1 / 192
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 192
Next page

Sort by:

Relevance

Page size

BCAT1 Confers Resistance to EGFR TKIs through α-KG-dependent Epigenetic Regulation of the Glycolysis Pathway in NSCLC

Epidermal growth factor receptor (EGFR) mutations are leading oncogenic drivers in non-small cell lung cancer (NSCLC). Many third-generation EGFR tyrosine kinase inhibitors (TKIs) have been developed to target EGFR T790M and activating mutations. Osimertinib (AZD9291) was the first approved drug and...

ORGANISM(S): Homo Sapiens

2023-07-14 | PXD043776 |

Analysis of the lncRNA-miRNA-mRNA network reveals a potential regulatory mechanism of EGFR-TKIs resistance in NSCLC

PRJNA796971 | ENA

Bevacizumab Plus EGFR-TKIs vs EGFR-TKIs Alone for Advanced EGFR-Mutant NSCLC: A Meta-Analysis.

Not available

S-EPMC12824130 | biostudies-literature

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.

Not available

S-EPMC11555867 | biostudies-literature

Analysis of the lncRNA-miRNA-mRNA network reveals a potential regulatory mechanism of EGFR-TKIs resistance in NSCLC

In this study, to investigate the underlying molecular mechanisms of how EGFR-TKIs resistance occurs in NSCLC, we examined gene expression using microarray technology on gefitinib-resistant NSCLC cells to obtain differentially expressed (DE) lncRNAs and mRNAs. Then we carried out KEGG enrichment ana...

ORGANISM(S): Homo sapiens

2022-01-14 | GSE193628 | GEO

HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.

Not available

S-EPMC7919131 | biostudies-literature

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.

Not available

S-EPMC4611484 | biostudies-literature

Novel agents and strategies for overcoming EGFR TKIs resistance.

Not available

S-EPMC3898214 | biostudies-literature

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.